https://wikimd.org/index.php?action=history&feed=atom&title=Muraglitazar 2026-04-29T23:24:14Z Revision history for this page on the wiki MediaWiki 1.44.2 https://wikimd.org/index.php?title=Muraglitazar&diff=6333357&oldid=prev 2025-02-20T01:17:41Z

<p>CSV import</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 01:17, 20 February 2025</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l24">Line 24:</td> <td colspan="2" class="diff-lineno">Line 24:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pharmacology]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pharmacology]]</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{Pharma-stub}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{Pharma-stub}}</div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">&lt;gallery&gt;</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">File:Muraglitazar.svg|Muraglitazar</ins></div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">&lt;/gallery&gt;</ins></div></td></tr> </table>

Prab https://wikimd.org/index.php?title=Muraglitazar&diff=5339947&oldid=prev 2024-03-02T02:45:32Z

<p>CSV import</p> <p><b>New page</b></p><div>&#039;&#039;&#039;Muraglitazar&#039;&#039;&#039; is a [[peroxisome proliferator-activated receptor]] (PPAR) agonist that was developed for the treatment of [[type 2 diabetes]]. It was designed to activate both PPAR-alpha and PPAR-gamma receptors, which are involved in [[glucose metabolism]] and [[lipid metabolism]], respectively. However, the drug was withdrawn from development due to concerns about its safety profile.<br /> <br /> == History ==<br /> <br /> Muraglitazar was developed by [[Bristol-Myers Squibb]] in the early 2000s. It was one of several dual PPAR agonists being developed at the time, which were hoped to provide better glucose control and lipid-lowering effects than the existing [[thiazolidinedione]] class of drugs. However, in 2006, Bristol-Myers Squibb announced that it was discontinuing development of muraglitazar due to concerns about its safety profile.<br /> <br /> == Mechanism of Action ==<br /> <br /> Muraglitazar acts as a dual PPAR agonist, activating both PPAR-alpha and PPAR-gamma receptors. PPAR-alpha receptors are primarily involved in lipid metabolism, and their activation can lead to reductions in [[triglyceride]] levels and increases in [[high-density lipoprotein]] (HDL) cholesterol. PPAR-gamma receptors, on the other hand, are involved in glucose metabolism, and their activation can improve insulin sensitivity and reduce blood glucose levels.<br /> <br /> == Safety Concerns ==<br /> <br /> The safety concerns that led to the discontinuation of muraglitazar primarily related to an increased risk of [[cardiovascular disease]]. In a meta-analysis of clinical trial data, muraglitazar was found to be associated with a significant increase in the risk of major adverse cardiovascular events, including heart attack and stroke. This led to the decision by Bristol-Myers Squibb to discontinue development of the drug.<br /> <br /> == See Also ==<br /> <br /> * [[Peroxisome proliferator-activated receptor]]<br /> * [[Type 2 diabetes]]<br /> * [[Bristol-Myers Squibb]]<br /> * [[Thiazolidinedione]]<br /> <br /> [[Category:Drugs]]<br /> [[Category:Diabetes]]<br /> [[Category:Pharmacology]]<br /> {{Pharma-stub}}</div>

Prab